Cargando…
Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date
The prevalence of type 2 diabetes (T2D) has increased worldwide and doubled over the last two decades. It features among the top 10 causes of mortality and morbidity in the world. Cardiovascular disease is the leading cause of complications in diabetes and within this, heart failure has been shown t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801309/ https://www.ncbi.nlm.nih.gov/pubmed/31641426 http://dx.doi.org/10.4239/wjd.v10.i10.490 |
_version_ | 1783460541671407616 |
---|---|
author | Athithan, Lavanya Gulsin, Gaurav S McCann, Gerald P Levelt, Eylem |
author_facet | Athithan, Lavanya Gulsin, Gaurav S McCann, Gerald P Levelt, Eylem |
author_sort | Athithan, Lavanya |
collection | PubMed |
description | The prevalence of type 2 diabetes (T2D) has increased worldwide and doubled over the last two decades. It features among the top 10 causes of mortality and morbidity in the world. Cardiovascular disease is the leading cause of complications in diabetes and within this, heart failure has been shown to be the leading cause of emergency admissions in the United Kingdom. There are many hypotheses and well-evidenced mechanisms by which diabetic cardiomyopathy as an entity develops. This review aims to give an overview of these mechanisms, with particular emphasis on metabolic inflexibility. T2D is associated with inefficient substrate utilisation, an inability to increase glucose metabolism and dependence on fatty acid oxidation within the diabetic heart resulting in mitochondrial uncoupling, glucotoxicity, lipotoxicity and initially subclinical cardiac dysfunction and finally in overt heart failure. The review also gives a concise update on developments within clinical imaging, specifically cardiac magnetic resonance studies to characterise and phenotype early cardiac dysfunction in T2D. A better understanding of the pathophysiology involved provides a platform for targeted therapy in diabetes to prevent the development of early heart failure with preserved ejection fraction. |
format | Online Article Text |
id | pubmed-6801309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-68013092019-10-22 Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date Athithan, Lavanya Gulsin, Gaurav S McCann, Gerald P Levelt, Eylem World J Diabetes Review The prevalence of type 2 diabetes (T2D) has increased worldwide and doubled over the last two decades. It features among the top 10 causes of mortality and morbidity in the world. Cardiovascular disease is the leading cause of complications in diabetes and within this, heart failure has been shown to be the leading cause of emergency admissions in the United Kingdom. There are many hypotheses and well-evidenced mechanisms by which diabetic cardiomyopathy as an entity develops. This review aims to give an overview of these mechanisms, with particular emphasis on metabolic inflexibility. T2D is associated with inefficient substrate utilisation, an inability to increase glucose metabolism and dependence on fatty acid oxidation within the diabetic heart resulting in mitochondrial uncoupling, glucotoxicity, lipotoxicity and initially subclinical cardiac dysfunction and finally in overt heart failure. The review also gives a concise update on developments within clinical imaging, specifically cardiac magnetic resonance studies to characterise and phenotype early cardiac dysfunction in T2D. A better understanding of the pathophysiology involved provides a platform for targeted therapy in diabetes to prevent the development of early heart failure with preserved ejection fraction. Baishideng Publishing Group Inc 2019-10-15 2019-10-15 /pmc/articles/PMC6801309/ /pubmed/31641426 http://dx.doi.org/10.4239/wjd.v10.i10.490 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Review Athithan, Lavanya Gulsin, Gaurav S McCann, Gerald P Levelt, Eylem Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date |
title | Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date |
title_full | Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date |
title_fullStr | Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date |
title_full_unstemmed | Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date |
title_short | Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date |
title_sort | diabetic cardiomyopathy: pathophysiology, theories and evidence to date |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801309/ https://www.ncbi.nlm.nih.gov/pubmed/31641426 http://dx.doi.org/10.4239/wjd.v10.i10.490 |
work_keys_str_mv | AT athithanlavanya diabeticcardiomyopathypathophysiologytheoriesandevidencetodate AT gulsingauravs diabeticcardiomyopathypathophysiologytheoriesandevidencetodate AT mccanngeraldp diabeticcardiomyopathypathophysiologytheoriesandevidencetodate AT levelteylem diabeticcardiomyopathypathophysiologytheoriesandevidencetodate |